文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

IMB-BZ作为靶向ESX-1分泌系统的抑制剂控制分枝杆菌感染

IMB-BZ as an Inhibitor Targeting ESX-1 Secretion System to Control Mycobacterial Infection.
PubMed 文献 · J Infect Dis · 2022-01-01

本研究建立高通量筛选方法发现ESX-1分泌抑制剂,命中化合物IMB-BZ可特异性抑制CFP-10分泌并以ESX-1依赖方式降低毒力,显著减少分枝杆菌胞内和体内存活。IMB-BZ通过阻断CFP-10-EccCb1相互作用发挥作用,体外诱导耐药风险低于传统抗结核药,对慢性感染高效,提示靶向ESX-1可开发新型抗结核药物。

要点

  • IMB-BZ特异性抑制ESX-1分泌CFP-10,不损害细菌体外生长。
  • IMB-BZ以ESX-1依赖方式降低毒力,减少分枝杆菌胞内和体内存活。
  • IMB-BZ体外诱导耐药风险低于传统抗结核药,对慢性感染高效。

核心结论

  • 靶向ESX-1可能开发新型结核治疗药物,IMB-BZ有潜力成为新抗结核药。

研究设计与样本

  • 研究建立高通量筛选方法发现ESX-1分泌抑制剂,并评估阳性命中化合物的效力、耐药诱导概率及机制。

主要发现

  • IMB-BZ特异性抑制CFP-10分泌,以ESX-1依赖方式降低毒力,显著减少分枝杆菌胞内和体内存活。
  • 直接或间接阻断CFP-10-EccCb1相互作用是IMB-BZ抑制CFP-10分泌的机制。
  • 体外比较显示ESX-1抑制剂诱导分枝杆菌耐药的风险低于传统抗结核药,且对慢性分枝杆菌感染高效。

临床怎么用

  • IMB-BZ作为ESX-1抑制剂候选,支持靶向ESX-1开发新型抗结核治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Resistance to anti-tuberculosis (TB) drugs is a major issue in TB control, and demands the discovery of new drugs targeting the virulence factor ESX-1. METHODS: We first established a high-throughput screen (HTS) assay for the discovery of ESX-1 secretion inhibitors. The positive hits were then evaluated for the potency of diminishing the survival of virulent mycobacteria and reducing bacterial virulence. We further investigated the probability of inducing drug resistance and the underlying mechanism using mycobacterial protein fragment complementation. RESULTS: A robust HTS assay was developed to identify small molecules that inhibit ESX-1 secretion without impairing bacterial growth in vitro. A hit named IMB-BZ specifically inhibits the secretion of CFP-10 and reduces virulence in an ESX-1-dependent manner, therefore resulting in significant reduction in intracellular and in vivo survival of mycobacteria. Blocking the CFP-10-EccCb1 interaction directly or indirectly underlies the inhibitory effect of IMB-BZ on the secretion of CFP-10. Importantly, our finding shows that the ESX-1 inhibitors pose low risk of drug resistance development by mycobacteria in vitro as compared with traditional anti-TB drugs, and exhibit high potency against chronic mycobacterial infection. CONCLUSIONS: Targeting ESX-1 may lead to the development of novel therapeutics for tuberculosis. IMB-BZ holds the potential for future development into a new anti-TB drug.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Jia P, Zhang Y, Xu J, et al. IMB-BZ as an Inhibitor Targeting ESX-1 Secretion System to Control Mycobacterial Infection. J Infect Dis. 2022. PMID: 34558604. doi:10.1093/infdis/jiab486

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。